Product Portfolio

Marketed Therapies

Below is a list of our company's marketed products. This information is intended only for U.S. residents.

For product information for other countries, please visit your country's Biogen affiliate website.

 

BENEPALI®  (etanercept) FLIXABI®  (infliximab)

BENEPALI® is the first etanercept biosimilar referencing Enbrel® approved in the European Union (EU). 

FAMPYRA® (prolonged-release fampridine tablets)

For further information on FAMPYRA in your country please click here.

U.S. residents: For information, please visit Acorda Therapeutics

 

FLIXABI®  (infliximab)

FLIXABI® is an infliximab biosimilar referencing Remicade® approved in the European Union (EU). 

IMRALDI™  (adalimumab)

IMRALDI™ is an adalimumab biosimilar referencing Humira® approved in Europe.

IMRALDIis expected to be available in Europe in October 2018.

 

 

PLEGRIDY®  (peginterferon beta-1a)

SPINRAZA®  (nusinersen)

ZINBRYTA®  (daclizumab)

On March 2, 2018, Biogen and AbbVie announced the voluntary worldwide withdrawal of marketing authorizations for ZINBRYTA® (daclizumab) for relapsing multiple sclerosis.

Read the full press release

U.S. Full Prescribing Information

Medication Guide

Product Website

 

 

Partnered Therapies

We have a collaboration agreement with Genentech that entitles us to certain business and financial rights with respect to RITUXAN, GAZYVA and OCREVUS. This information is intended only for U.S. residents.